Founded in 2018, 新格元生物 focuses on autonomous development and clinical translation of high-throughput single-cell multi-omics platforms. The company offers an integrated, one-stop single-cell sequencing solution covering tissue processing, high-throughput single-cell isolation, library construction, data analysis, and clinical interpretation. Its products include the Singleron Matrix™ automated single-cell library construction instrument, GEXSCOPE® high-throughput single-cell sequencing kits, CeleScope™ bioinformatics software, and the SynEcoSys™ single-cell database. 新格元 has served more than 160 hospitals, pharmaceutical companies, and research institutes. The company plans to accelerate platform product development and clinical application translation, advance single-cell sequencing and data use in drug development, commercialize products domestically, and pursue international operations. Financially, 新格元 completed a $30 million Series A and reports total financing to date exceeding ¥300 million RMB.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020